BI 3000202, BI 3000202, Placebo matching BI 3000202 clinical trials

Randomised, placebo-controlled, double-blind, parallel-group Phase II study to evaluate the efficacy and safety of oral BI 3000202 in patients with moderate to severe systemic lupus erythematosus (SLE)

This study is testing a new medicine, BI 3000202, for people with moderate to severe lupus. Researchers want to see if it helps reduce lupus symptoms and is safe. Some people will get the new medicine, others a dummy pill. It lasts about 32 weeks.